The JDRF and the Helmsley Charitable Trust Request Expressions of Interest for Improved Assays for Predicting Risk for T1D

The JDRF and the Helmsley Charitable Trust Request Expressions of Interest for Improved Assays for Predicting Risk for T1D JDRF and The Leona M. and Harry B. Helmlsey Charitable Trust are soliciting expressions of interest (EOI) for optimizing and validating existing technologies for predictive screening for T1D risk and autoimmunity to be applied for wide-spread use in population-based screening efforts, including newborn or childhood based screening. EOIs requesting development of new assays will not be considered. BACKGROUND Prevention of type 1 diabetes (T1D) represents a “cure” for those at-risk of developing the disease, and, in fact, will likely represent the most cost-effective approach to a cure and is becoming increasingly important with the rising incidence of the disease. Over the last three to four decades, the incidence of T1D has increased at an annual rate of 3-5% with penetration to low-moderate human leukocyte antigen (HLA) risk groups, suggesting a lowered threshold for its development. In some countries, the largest increase in incidence has occurred in the age group 1-5 years. Currently, assays of islet autoantibodies (AAb) are the most robust approach to detect risk in relatives of individuals with T1D and aid in predicting progression to T1D in HLA at-risk children. Indeed , the 10-year risk of progression to symptomatic T1D with multiple islet AAbs (insulin, GAD65, IA-2 and ZnT8) is 70%. However, the current practices for AA...
Source: ScanGrants feed - Category: Research Authors: Source Type: funding